NasdaqGM:STROBiotechs
Sutro Biopharma Q3 Loss Of US$56.9 Million Tests Profitability Narratives For STRO Investors
Latest FY 2025 Results: Revenue Pressure and Deep Losses at Sutro Biopharma (STRO)
Sutro Biopharma (STRO) has put out fresh FY 2025 numbers, with Q3 total revenue of US$9.7 million, a basic EPS loss of US$6.70, and net income loss excluding extra items of US$56.9 million setting the tone for the update. The company has seen quarterly revenue move between US$8.5 million and US$63.7 million over the last six reported periods, while basic EPS has ranged from a loss of US$1.36 to a loss of...